Taking Fancl fully private via a tender offer (2024)

A field where a “wait-and-see” capital tie no longer works

At the heart of this decision is a recognition that a minority stake — a capital tie held to “wait and see” — does not suit a field like health science, which demands long-horizon research investment and business design. Over the five years since becoming Fancl’s largest shareholder in 2019, Kirin appears to have learned first-hand where the line falls between what a partnership can do and what only full integration can do. However much it tried to unify research and product strategy while Fancl remained a listed subsidiary, deference to minority shareholders bound both the speed and the depth of its decisions. Moving step by step from alliance to outright subsidiary can be read as the process of arriving at a single conclusion: unless you move the capital structure itself, the distance between strategy and execution will not close.

That said, the road to full ownership was not smooth. After the offer opened, the share price rose above the tender price and an investment fund kept buying, forcing Kirin to raise its price and extend the offer period three times to gather enough shares. In taking a listed subsidiary private, the interests of minority shareholders surface through the price and push up the terms of acquisition. The integration Kirin had sketched at roughly $1.5B (¥220bn) came to fruition only after negotiations with minority shareholders had piled on extra cost. Just as the seriousness of a strategy shows up in the capital structure, how much one is willing to pay to match that seriousness is itself the question that taking a listed subsidiary private forces to the surface.